Primary Site >> Pancreatic Cancer
Gene >> NQO1
| 1. | |||||||||||
| Journal: | Gan To Kagaku Ryoho. 1993 Jun;20(8):1037-41. | ||||||||||
| Title: | [Mitomycin C and its bioreduction: relevance of NAD(P)H: quinone oxidoreductase activity to mitomycin C-induced DNA damage and cytotoxicity]. | ||||||||||
| Author: | Nishiyama, M|Saeki, S|Aogi, K|Hirabayashi, N|Toge, T | ||||||||||
| PMID: | 7685584 | ||||||||||
| 2. | |||||||||||
| Journal: | Eur J Cancer Prev. 1998 Jun;7(3):215-23. | ||||||||||
| Title: | Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. The International Pancreatic Disease Study Group. | ||||||||||
| Author: | Bartsch, H|Malaveille, C|Lowenfels, A B|Maisonneuve, P|Hautefeuille, A|Boyle, P | ||||||||||
| PMID: | 9696930 | ||||||||||
| 3. | |||||||||||
| Journal: | Cancer Res. 2003 Sep 1;63(17):5513-20. | ||||||||||
| Title: | Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. | ||||||||||
| Author: | Cullen, Joseph J|Hinkhouse, Marilyn M|Grady, Matthew|Gaut, Andrew W|Liu, Jingru|Zhang, Yu Ping|Weydert, Christine J Darby|Domann, Frederick E|Oberley, Larry W | ||||||||||
| PMID: | 14500388 | ||||||||||
| 4. | |||||||||||
| Journal: | Clin Cancer Res. 2004 Jul 1;10(13):4550-8. | ||||||||||
| Title: | Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. | ||||||||||
| Author: | Lewis, Anne|Ough, Matthew|Li, Ling|Hinkhouse, Marilyn M|Ritchie, Justine M|Spitz, Douglas R|Cullen, Joseph J | ||||||||||
| PMID: | 15240547 | ||||||||||
| 5. | |||||||||||
| Journal: | Cancer Biol Ther. 2005 Jan;4(1):95-102. Epub 2005 Jan 15. | ||||||||||
| Title: | Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. | ||||||||||
| Author: | Ough, Matthew|Lewis, Anne|Bey, Erik A|Gao, Jinming|Ritchie, Justine M|Bornmann, William|Boothman, David A|Oberley, Larry W|Cullen, Joseph J | ||||||||||
| PMID: | 15662131 | ||||||||||
| 6. | |||||||||||
| Journal: | Mol Carcinog. 2005 Aug;43(4):215-24. | ||||||||||
| Title: | Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. | ||||||||||
| Author: | Lewis, Anne M|Ough, Matthew|Hinkhouse, Marilyn M|Tsao, Ming-Sound|Oberley, Larry W|Cullen, Joseph J | ||||||||||
| PMID: | 16003741 | ||||||||||
| 7. | |||||||||||
| Journal: | Cell Biol Toxicol. 2006 Mar;22(2):73-80. Epub 2006 Mar 9. | ||||||||||
| Title: | Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas. | ||||||||||
| Author: | Lyn-Cook, B D|Yan-Sanders, Y|Moore, S|Taylor, S|Word, B|Hammons, G J | ||||||||||
| PMID: | 16532285 | ||||||||||
| 8. | |||||||||||
| Journal: | Mol Cancer Ther. 2006 Jul;5(7):1702-9. | ||||||||||
| Title: | 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. | ||||||||||
| Author: | Dehn, Donna L|Siegel, David|Zafar, Khan Shoeb|Reigan, Philip|Swann, Elizabeth|Moody, Christopher J|Ross, David | ||||||||||
| PMID: | 16891456 | ||||||||||
| 9. | |||||||||||
| Journal: | J Biol Chem. 2006 Dec 8;281(49):37416-26. | ||||||||||
| Title: | Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells. | ||||||||||
| Author: | Du, Juan|Daniels, David H|Asbury, Carla|Venkataraman, Sujatha|Liu, Jingru|Spitz, Douglas R|Oberley, Larry W|Cullen, Joseph J | ||||||||||
| PMID: | 17040906 | ||||||||||
| 10. | |||||||||||
| Journal: | Biochemistry. 2007 May 22;46(20):5941-50. Epub 2007 Apr 25. | ||||||||||
| Title: | Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. | ||||||||||
| Author: | Reigan, Philip|Colucci, Marie A|Siegel, David|Chilloux, Aurelie|Moody, Christopher J|Ross, David | ||||||||||
| PMID: | 17455910 | ||||||||||
| 11. | |||||||||||
| Journal: | J Med Chem. 2007 Dec 13;50(25):6316-25. | ||||||||||
| Title: | Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. | ||||||||||
| Author: | Nolan, Karen A|Zhao, He|Faulder, Paul F|Frenkel, A David|Timson, David J|Siegel, David|Ross, David|Burke, Terrence R Jr|Stratford, Ian J|Bryce, Richard A | ||||||||||
| PMID: | 17999461 | ||||||||||
| 12. | |||||||||||
| Journal: | J Med Chem. 2007 Nov 15;50(23):5780-9. Epub 2007 Oct 18. | ||||||||||
| Title: | Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity. | ||||||||||
| Author: | Colucci, Marie A|Reigan, Philip|Siegel, David|Chilloux, Aurelie|Ross, David|Moody, Christopher J | ||||||||||
| PMID: | 17944451 | ||||||||||
| 13. | |||||||||||
| Journal: | Cancer Res. 2007 Jul 15;67(14):6936-45. | ||||||||||
| Title: | Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. | ||||||||||
| Author: | Bentle, Melissa S|Reinicke, Kathryn E|Dong, Ying|Bey, Erik A|Boothman, David A | ||||||||||
| PMID: | 17638905 | ||||||||||
| 14. | |||||||||||
| Journal: | Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):24-31. | ||||||||||
| Title: | NQO1 expression in pancreatic cancer and its potential use as a biomarker. | ||||||||||
| Author: | Awadallah, Nida S|Dehn, Donna|Shah, Raj J|Russell Nash, S|Chen, Yang K|Ross, David|Bentz, Joel S|Shroyer, Kenneth R | ||||||||||
| PMID: | 18091324 | ||||||||||
| 15. | |||||||||||
| Journal: | Org Biomol Chem. 2008 Feb 21;6(4):637-56. | ||||||||||
| Title: | Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. | ||||||||||
| Author: | Colucci, Marie A|Moody, Christopher J|Couch, Gavin D | ||||||||||
| PMID: | 18264564 | ||||||||||
| 16. | |||||||||||
| Journal: | J Med Chem. 2009 Nov 26;52(22):7142-56. | ||||||||||
| Title: | Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). | ||||||||||
| Author: | Nolan, Karen A|Doncaster, Jeremy R|Dunstan, Mark S|Scott, Katherine A|Frenkel, A David|Siegel, David|Ross, David|Barnes, John|Levy, Colin|Leys, David|Whitehead, Roger C|Stratford, Ian J|Bryce, Richard A | ||||||||||
| PMID: | 19877692 | ||||||||||
| 17. | |||||||||||
| Journal: | Pancreas. 2011 Jan;40(1):72-8. | ||||||||||
| Title: | Superoxide dismutase and nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase polymorphisms and pancreatic cancer risk. | ||||||||||
| Author: | Mohelnikova-Duchonova, Beatrice|Marsakova, Lenka|Vrana, David|Holcatova, Ivana|Ryska, Miroslav|Smerhovsky, Zdenek|Slamova, Alena|Schejbalova, Miriam|Soucek, Pavel | ||||||||||
| PMID: | 20966810 | ||||||||||
| 18. | |||||||||||
| Journal: | Clin Cancer Res. 2011 Jan 15;17(2):275-85. | ||||||||||
| Title: | Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. | ||||||||||
| Author: | Li, Long Shan|Bey, Erik A|Dong, Ying|Meng, Jieru|Patra, Biswanath|Yan, Jingsheng|Xie, Xian-Jin|Brekken, Rolf A|Barnett, Carlton C|Bornmann, William G|Gao, Jinming|Boothman, David A | ||||||||||
| PMID: | 21224367 | ||||||||||
| 19. | |||||||||||
| Journal: | J Pharmacol Exp Ther. 2011 Mar;336(3):874-80. | ||||||||||
| Title: | Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. | ||||||||||
| Author: | Siegel, David|Shieh, Biehuoy|Yan, Chao|Kepa, Jadwiga K|Ross, David | ||||||||||
| PMID: | 21156818 | ||||||||||
| 20. | |||||||||||
| Journal: | PLoS One. 2012;7(9):e44861. | ||||||||||
| Title: | NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells. | ||||||||||
| Author: | Siegel, David|Kepa, Jadwiga K|Ross, David | ||||||||||
| PMID: | 22984577 | ||||||||||
| 21. | |||||||||||
| Journal: | Mol Imaging Biol. 2014 Feb;16(1):85-94. | ||||||||||
| Title: | Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. | ||||||||||
| Author: | Kim, Hyunki|Rigell, Christopher J|Zhai, Guihua|Lee, S Kyle|Samuel, Sharon L|Martin, Amber|Umphrey, Heidi R|Stockard, Cecil R|Beasley, T Mark|Buchsbaum, Donald J|Li, Long Shan|Boothman, David A|Zinn, Kurt R | ||||||||||
| PMID: | 23836505 | ||||||||||
| 22. | |||||||||||
| Journal: | Clin Pharmacol. 2015 Mar 27;7:57-68. | ||||||||||
| Title: | Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. | ||||||||||
| Author: | Chakrabarti, Gaurab|Gerber, David E|Boothman, David A | ||||||||||
| PMID: | 25870517 | ||||||||||
| 23. | |||||||||||
| Journal: | Biochimie. 2015 Sep;116:141-53. | ||||||||||
| Title: | Combinative effects of beta-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation. | ||||||||||
| Author: | Breton, Caroline S|Aubry, Dominique|Ginet, Vanessa|Puyal, Julien|Heulot, Mathieu|Widmann, Christian|Duchosal, Michel A|Nahimana, Aimable | ||||||||||
| PMID: | 26188110 | ||||||||||
| 24. | |||||||||||
| Journal: | Mol Pharm. 2015 Nov 2;12(11):3999-4010. | ||||||||||
| Title: | beta-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. | ||||||||||
| Author: | Zhang, Ling|Chen, Zhen|Yang, Kuan|Liu, Chun|Gao, Jinming|Qian, Feng | ||||||||||
| PMID: | 26415823 | ||||||||||
| 25. | |||||||||||
| Journal: | Cancer Metab. 2015 Oct 12;3:12. | ||||||||||
| Title: | Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone. | ||||||||||
| Author: | Chakrabarti, Gaurab|Moore, Zachary R|Luo, Xiuquan|Ilcheva, Mariya|Ali, Aktar|Padanad, Mahesh|Zhou, Yunyun|Xie, Yang|Burma, Sandeep|Scaglioni, Pier P|Cantley, Lewis C|DeBerardinis, Ralph J|Kimmelman, Alec C|Lyssiotis, Costas A|Boothman, David A | ||||||||||
| PMID: | 26462257 | ||||||||||
| 26. | |||||||||||
| Journal: | Sci Rep. 2015 Nov 25;5:17066. | ||||||||||
| Title: | Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, beta-lapachone. | ||||||||||
| Author: | Chakrabarti, Gaurab|Silvers, Molly A|Ilcheva, Mariya|Liu, Yuliang|Moore, Zachary R|Luo, Xiuquan|Gao, Jinming|Anderson, Glenda|Liu, Lili|Sarode, Venetia|Gerber, David E|Burma, Sandeep|DeBerardinis, Ralph J|Gerson, Stanton L|Boothman, David A | ||||||||||
| PMID: | 26602448 | ||||||||||
| 27. | |||||||||||
| Journal: | Mol Cancer. 2016 Oct 18;15(1):64. | ||||||||||
| Title: | Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1. | ||||||||||
| Author: | Arora, Rashi|Sawney, Sharad|Saini, Vikas|Steffi, Chris|Tiwari, Manisha|Saluja, Daman | ||||||||||
| PMID: | 27756327 | ||||||||||
| 28. | |||||||||||
| Journal: | J Surg Oncol. 2017 Jul;116(1):83-88. | ||||||||||
| Title: | Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. | ||||||||||
| Author: | Beg, Muhammad Shaalan|Huang, Xiumei|Silvers, Molly A|Gerber, David E|Bolluyt, Joyce|Sarode, Venetia|Fattah, Farjana|Deberardinis, Ralph J|Merritt, Matthew E|Xie, Xian-Jin|Leff, Richard|Laheru, Daniel|Boothman, David A | ||||||||||
| PMID: | 28346693 | ||||||||||
| 29. | |||||||||||
| Journal: | Oncol Lett. 2017 May;13(5):2996-3002. | ||||||||||
| Title: | Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. | ||||||||||
| Author: | Ji, Meiying|Jin, Aihua|Sun, Jie|Cui, Xuelian|Yang, Yang|Chen, Liyan|Lin, Zhenhua | ||||||||||
| PMID: | 28521407 | ||||||||||
| 30. | |||||||||||
| Journal: | Mol Carcinog. 2017 Jul;56(7):1825-1834. | ||||||||||
| Title: | Targeting NAD(P)H:Quinone Oxidoreductase (NQO1) in Pancreatic Cancer. | ||||||||||
| Author: | Lewis, Anne M|Ough, Matthew|Du, Juan|Tsao, Ming-Sound|Oberley, Larry W|Cullen, Joseph J | ||||||||||
| PMID: | 28639725 | ||||||||||
| 31. | |||||||||||
| Journal: | J Biol Chem. 2017 Nov 3;292(44):18203-18216. | ||||||||||
| Title: | The NQO1 bioactivatable drug, beta-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. | ||||||||||
| Author: | Silvers, Molly A|Deja, Stanislaw|Singh, Naveen|Egnatchik, Robert A|Sudderth, Jessica|Luo, Xiuquan|Beg, Muhammad S|Burgess, Shawn C|DeBerardinis, Ralph J|Boothman, David A|Merritt, Matthew E | ||||||||||
| PMID: | 28916726 | ||||||||||
| 32. | |||||||||||
| Journal: | J Med Chem. 2018 Feb 22;61(4):1576-1594. | ||||||||||
| Title: | Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. | ||||||||||
| Author: | Kuang, Yuting|Sechi, Mario|Nurra, Salvatore|Ljungman, Mats|Neamati, Nouri | ||||||||||
| PMID: | 29328656 | ||||||||||
| 33. | |||||||||||
| Journal: | Curr Oncol Rep. 2018 May 11;20(7):56. | ||||||||||
| Title: | Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications. | ||||||||||
| Author: | Hosein, Abdel Nasser|Beg, Muhammad Shaalan | ||||||||||
| PMID: | 29752600 | ||||||||||